Biodesix, Inc. (BDSX) AI Stock Analysis

Biodesix, Inc. is a data-driven diagnostic solutions company operating in the United States, specializing in advanced lung cancer diagnostics. Its flagship offerings include the Nodify XL2 and Nodify CDT blood-based tests, which form part of its Nodify Lung Nodule Risk Assessment strategy to help physicians evaluate malignancy risk in lung nodules. The company also offers the GeneStrat ddPCR, VeriStrat, and the 72-hour blood-based GeneStrat NGS tests to detect mutations and monitor immune status. In partnership with Bio-Rad Laboratories, Inc., it provides COVID-19 tests under the Biodesix WorkSafe program, alongside clinical research and companion diagnostic services for biopharmaceutical firms.

Biodesix grew annual revenue from $54.5M in FY2021 to $88.5M in FY2025, yielding a 5-year revenue CAGR of 14.2%. Over that span, gross margin improved from 44.0% in FY2021 to 81.1% in FY2025. Although net losses narrowed from -$65.4M in FY2022 to -$35.3M in FY2025, operating margin remained negative at -31.4% in FY2025. For the trailing twelve months, revenue reached $102.9M with an operating margin of -20.0% and an EPS of -$3.10. In the latest quarter ended June 30, 2026, quarterly revenue grew 34.2% year-over-year.

As of June 30, 2026, Biodesix held $30.0M in cash and short-term investments against $71.8M in total debt, resulting in net debt of $41.8M and a debt-to-equity ratio of 7.85. Total assets stood at $95.3M with a current ratio of 2.85. The company remains cash-flow negative, reporting an operating cash flow of -$23.3M and free cash flow of -$23.7M in FY2025. During FY2025, capital expenditures were $403,000, while share issuance contributed $497,000 following a 5-year share count change of 660.9%.

At a share price of $23.66 and a market capitalization of $249.6M, Biodesix trades at a price-to-sales multiple of 2.4x and an enterprise-value-to-revenue multiple of 3.4x. Its price-to-sales ratio sits below the 4.1x median of its US-listed Healthcare peers. Over the past year, the stock returned 240.4%, outperforming the S&P 500 (SPY) return of 16.8%. However, its 5-year return stands at -84.2%, compared to an 83.0% gain for the benchmark.

Wall Street coverage consists of 7 Strong Buy ratings, 0 Buys, 0 Holds, and 0 Sells. The mean price target of $39.00 indicates a 64.8% premium over the last close of $23.66. Consensus estimates project FY2026 revenue of $112.0M with an EPS of -$2.67, and FY2027 revenue of $134.6M with an EPS of -$1.67. Over the last 4 quarters, the company delivered 4 EPS beats. The next earnings date is November 2, 2026.

This page is an AI-written research summary of Biodesix, Inc. (BDSX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BDSX income statement, BDSX balance sheet, BDSX key metrics, BDSX analyst forecast, BDSX chart. See the BDSX stock overview for the latest quote and news.